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Abstract 52 
Airway hyperresponsiveness (AHR) is a critical feature of wheezing and asthma in children, 53 
but the initiating immune mechanisms remain unconfirmed. We demonstrate that both rIL-33 54 
and allergen (house dust mite (HDM), or Alternaria alternata) exposure from day 3 of life 55 
resulted in significantly increased pulmonary IL-13+CD4+ T cells which were indispensable for 56 
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the development of AHR. In contrast, adult mice had a predominance of pulmonary 57 
LinnegCD45+CD90+IL-13+ innate lymphoid cells (ILC2s) following administration of rIL-33. 58 
HDM exposure of neonatal IL-33KO mice still resulted in AHR. However, neonatal CD4creIL-59 
13 KO mice (lacking IL-13+CD4+ T cells) exposed to allergen from day 3 of life were protected 60 
from AHR despite persistent pulmonary eosinophilia, elevated IL-33 levels and IL-13+ ILCs. 61 
Moreover, neonatal mice were protected from AHR when inhaled Acinetobacter Iwoffii (an 62 
environmental bacterial isolate found in cattle farms which is known to protect from childhood 63 
asthma) was administered concurrent with HDM. A. Iwoffii blocked the expansion of 64 
pulmonary IL-13+CD4+ T cells while IL-13+ ILCs and IL-33 remained elevated. Administration 65 
of A. Iwoffii mirrored the findings from the CD4creIL-13 KO mice, providing a translational 66 
approach for disease protection in early life. These data demonstrate that IL-13+CD4+ T cells, 67 
rather than IL-13+ ILCs or IL-33 are critical for inception of allergic airways 68 
hyperresponsiveness in early life. 69 
 70 
 71 
 72 
  73 
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Introduction 74 
The key pathophysiological abnormalities of allergic asthma include airway 75 
hyperresponsiveness (AHR), eosinophilic inflammation and remodelling (1). Childhood onset 76 
disease is common, affecting approximately 10% of children, and is characterised by the key 77 
clinical symptom of recurrent wheeze (2). Approximately one-third of all children develop 78 
wheezing in the first 5 years of life, but only one-third of those will develop asthma (3). 79 
However, the mechanisms by which allergic immune responses are initiated and the factors 80 
that mediate onset of pre-school wheezing and progression to asthma are currently unidentified 81 
(4, 5). AHR is a central feature of recurrent wheezing in children who develop asthma, and 82 
impaired lung function (6, 7) and AHR shortly after birth  (8, 9), are known to be associated 83 
with asthma in adolescence and adulthood (10).  84 
 85 
The importance of innate immunity, specifically innate lymphoid cells (ILCs), in the inception 86 
of allergic asthma is increasingly proposed  (11). However, during pregnancy there is a change 87 
in the uterine environment towards a Th2 cytokine profile and the thymic microenvironment is 88 
Th2-skewed in the early postnatal period and undergoes age-related suppression in favor of 89 
increasing Th1 maturation  (12).  Despite this, the current dogma is that pulmonary type 2 ILCs, 90 
not CD4+ T cells, are the primary cellular source of type 2 cytokines (IL-5 and IL-13) in early 91 
life (13). Even though allergic asthma begins in childhood (14) , mechanistic studies of allergic 92 
airways disease had predominantly used adult experimental models  (15-17), thus disregarding 93 
the specific developmental effects of postnatal immune maturation (18). A number of recent 94 
studies have utilized age appropriate murine neonatal models and have demonstrated that in 95 
C57BL/6 mice perinatal type 2 immunity depends on IL-33 which is immediately upregulated 96 
from the first day of life and drives accumulation and activation of IL-13 secreting ILC2s and 97 
pulmonary eosinophils following house dust mite exposure (13, 19, 20). However, the 98 
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predominant clinical manifestation in infants and pre-school children is recurrent wheezing 99 
with associated AHR and reduced lung function (21), but neonatal studies to date have not 100 
investigated the mechanisms driving AHR. 101 
 102 
Age dependent maturation of the immune system occurs following birth once the neonate 103 
encounters the antigen rich external environment  (22) . The composition of the airway bacterial 104 
profile in utero and in early life is also important since exposure to a diverse bacterial mix, 105 
such as that found on traditional cattle farms has been shown to protect from the development 106 
of allergy and asthma (23, 24).  The capacity of the adaptive immune system to induce memory 107 
responses is limited and is thought to gradually develop following early-life environmental 108 
exposure to microbes, pollutants and allergens (25). Interestingly, a population of fetally 109 
derived CD4+ T cells with an effector memory phenotype are present in cord blood. These cells 110 
develop during fetal life but have a variety of effector inflammatory functions associated with 111 
CD4+ T helper cells at birth (26). However, little is known about the phenotype or function of 112 
tissue specific (pulmonary) effector T cells in early life. Studies in infants have shown allergen 113 
induced immune responses in whole blood mononuclear cells can be detected at birth with IL-114 
13 predominating following stimulation with the egg protein ovalbumin (27). A differential 115 
developmental pattern of IL-13 vs IL-4, IL-5, and IFN-γ production was evident in infants in 116 
the first 3 months of life  (28). Although these data implicate IL-13 in the inception of early 117 
life allergic immune responses in children, there is little direct mechanistic evidence, 118 
particularly for identification of a cellular source for IL-13 during this crucial period. 119 
 120 
We have previously demonstrated that exposure of neonatal mice from day 3 of life to inhaled 121 
house dust mite (HDM) promotes robust eosinophilia, Th2 type immune responses and AHR 122 
(29). We show here that the cellular source of type 2 mediators in neonatal mice is not restricted 123 
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to ILCs but that IL-13 secreting CD4+ T cells are crucial for the development of AHR in early 124 
life. Additionally, we show that IL-33, which is elevated in school-age children with severe 125 
asthma, and has been linked to airway remodelling, is not a requirement for the initiation of 126 
allergic airways disease. Moreover, protection from AHR was achieved in neonatal mice using 127 
inhaled farmyard bacteria administered concomitantly with HDM, with a selective reduction 128 
in IL-13+CD4+ T cells and IL-13, despite elevated IL-33 and IL-13+ ILCs. Our data 129 
demonstrate the cellular source of IL-13 is essential in determining the development of early 130 
life AHR and underpins the concept of a window of immune development in early life that has 131 
implications for development of AHR.  132 
 133 
Results 134 
IL-13+CD4+T cells are induced by IL-33 in neonatal mice. 135 
IL-33 is sufficient to generate allergic airway responses in adult mice via the induction of type 136 
2 ILCs, and without the development of an adaptive immune response (30).  Whilst ILCs have 137 
been shown to drive type 2 immunity in some models, their role in initiating AHR in early life 138 
has not been investigated. In order to determine whether ILCs are also the predominant cellular 139 
source of IL-13 in neonatal mice, we delivered intra-nasal rIL-33 for 2 weeks to adult mice or 140 
neonatal mice from day 3 of life (Fig. 1A) and enumerated IL-13+CD4+ T cells and ILCs by 141 
flow cytometry (fig. S1, A and B). There are numerous published strategies to define an ILC, 142 
using combinations of extracellular markers and intracellular cytokine or transcription factor 143 
expression (31). However, expression of cell surface markers by ILCs is variable and context-144 
dependent (32). Given the importance of IL-13 in driving the pathological features of early life 145 
airway disease we focussed on cytokine secreting cells, initially gating on pulmonary 146 
LinnegCD45+IL-13+ cells and then examined the expression of the extracellular ILC markers 147 
CD127, CD90, CD25, ST2 and ICOS within this population (fig. S1C). We found that in 148 
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neonatal BALB/c mice only CD90 reliably marked the IL-13+ ILC population at steady state 149 
and during IL-33-driven inflammation (fig. S1C), therefore we used LinnegCD45+CD90+IL-13+ 150 
as our definition for ILC2. ST2, CD25 and ICOS were variable expressed, being present on 151 
only 30-40% of ILC2 at baseline (PBS treated) although this increased to 75% on rIL-33 152 
induced ILC2 (fig. S1C & D). CD127 staining showed little separation from fluorescence 153 
minus one controls in BALB/c ILC2s under all conditions tested (fig. S1E), precluding its 154 
usefulness as a definitive marker of ILC2 populations in this strain of mice. Notably, more 155 
substantial CD127 staining was observed on ILC2 in C57BL/6 mice, both at steady state and 156 
during allergic airway inflammation (fig. S1E), suggesting that strain differences exist in 157 
murine ILC2 surface phenotype. Importantly, LinnegCD45+CRTH2+ ILC2 in children with 158 
STRA are also predominantly CD127neg (33). Collectively, these findings rationalise the use of 159 
LinnegCD45+CD90+ IL-13+ as a robust definition of functional IL-13 producing ILC2 in 160 
neonatal BALB/c mice. 161 
There was a significant difference in the balance of IL-13+ lymphoid cellular phenotypes 162 
observed in the lungs of adult and neonatal mice exposed to the innate cytokine rIL-33. In adult 163 
mice, as expected the effect was predominantly on induction of IL-13+ ILCs, compared to IL-164 
13+CD4+ T cells (CD3+CD4+) (Fig. 1B). In contrast, neonatal mice responded to rIL-33 with 165 
comparable increases in levels of both IL-13+CD4+ T cells and IL-13+ ILCs (Fig. 1C). Both 166 
adult and neonatal mice developed significant eosinophilia following challenge with rIL-33 167 
and this response was greatest in adult mice (Fig 1D). In addition, rIL-33 increased airway 168 
resistance at both ages, concomitant with increased IL-13 levels (Fig. 1 E-H). Levels of IL-5 169 
were also increased in mice of both ages although the magnitude of the response was greatest 170 
in adult mice (Fig. 1I). Although 2 weeks exposure to cytokine is too short to observe 171 
phenotypic changes in airway remodelling, increases in the mucin genes Muc5ac and Muc5b, 172 
the principle components of airway mucous, were observed in both neonatal and adult mice 173 
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(Fig. 1 J&K). Muc5ac has been demonstrated to be necessary for the development of AHR, is 174 
increased in asthmatic patients including children and is regulated by levels of IL-13 (34). 175 
 176 
Both T cells and ILC comprise the neonatal response to allergen. 177 
To determine the cellular source of IL-13 following exposure to an antigenically complex, 178 
clinically relevant allergen, we compared intra-nasal HDM exposure for 2 weeks in neonatal 179 
mice from day 3 of life to adult mice (Fig. 2). Duration of allergen exposure was limited to 2 180 
weeks in order to focus on mechanisms underlying disease inception, before established 181 
adaptive allergic immunity with elevated IgE levels. Both neonatal and adult mice developed 182 
AHR (Fig. 2, A and B) and eosinophilia (Fig. 2C) in response to allergen.  In contrast to the 183 
immune response to rIL-33, which in adult mice skewed the IL-13 secreting cells towards an 184 
ILC2 dominated response, HDM resulted in significantly elevated numbers of IL-13+CD4+ T 185 
cells (Fig. 2D). In contrast, neonatal mice exposed to HDM had a mixed response with 186 
induction of both Th2 and ILC2s (Fig. 2E). However, significantly more IL-13+CD4+ T cells 187 
were induced compared to IL-13+ ILCs (Fig 2E). The increase in IL-13+ cells, irrespective of 188 
their source resulted in elevated levels of pulmonary IL-13 in adult and neonatal mice (Fig. 189 
2F). To extend our observations to another clinically relevant allergen we enumerated ILCs 190 
and T cells following exposure to the fungal allergen Alternaria alternata (fig. S2A), which is 191 
associated with severe paediatric asthma (35) and with elevated pulmonary IL-33 (36). In both 192 
adult and neonatal mice inhaled Alternaria induced a strong inflammatory response with 193 
significant elevations of both IL-13+CD4+ T cells and IL-13+ ILCs (Fig. 2, G and H) with 194 
associated increased levels of IL-13 (Fig. 2I). The elevated IL-13 concentration in the lung 195 
correlated with increased AHR (fig. S2, B and C). Congruent with a type 2 inflammatory 196 
response both adult and neonatal mice exhibited significant pulmonary eosinophilia (fig. S2D). 197 
 198 
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We next phenotyped the allergen induced T cells present in neonatal lungs and compared them 199 
to adults. In the CD4+IL-13neg population the proportion of cells with a memory like phenotype 200 
(CD44+ CD62Llow/-) was equivalent in adults and neonates (Fig. 3, A and B), whereas the 201 
percentage expressing CD103, an integrin associated with epithelial lymphocyte localisation, 202 
and the activation markers CD69 and ICOS was greater in adults compared to neonates (Fig. 203 
3, C - F). Examination of the CD4+IL-13+ T cells revealed similar patterns of extracellular 204 
marker expression in cells recovered from both HDM and Alternaria treated mice although the 205 
proportions of cells expressing specific markers was greatest in mice administered Alternaria. 206 
In contrast to the IL-13neg population, the proportion of IL-13+CD4+ T cells with a memory like 207 
phenotype was significantly higher in neonates than adults (Fig. 3, A and B). Likewise, more 208 
neonatal IL-13+CD4+ T cells expressed CD103 than adults after HDM (Fig. 3, C and D). A 209 
very high proportion of cells expressed CD69 and ICOS in adults and neonatal mice exposed 210 
to either HDM or Alternaria (Fig. 3, E and F). Thus, the effector T cells in neonatal lungs, far 211 
from having an immature phenotype appear analogous to adult T cells.   212 
We next characterised the intra-cellular cytokine profile of the T cells. At baseline (PBS control 213 
mice) the majority of neonatal cytokine producing CD3+CD4+ cells had the capacity to secrete 214 
IFN- and IL-17, whereas this was more limited in cells from adult mice (Fig. 3, G and H). 215 
HDM elicited a mixed T cell response with an increase in the proportion of Th2 (IL-5+ or IL-216 
13+), Th1 (IFN-) and regulatory (IL-10+) T cells in both adults and neonates (Fig. 3, I and J). 217 
One notable difference in the T cell response to HDM between adults and neonates is that in 218 
neonates a high proportion of IL-13+CD4+ T cells co-express IL-5 but in adults these dual 219 
positive cells are relatively rare. Exposure to Alternaria stimulated the greatest proliferation of 220 
CD4+ T cells which predominantly generated IL-13 or IL-17 in neonates (Fig. 3K).  In adult 221 
mice Alternaria polarised T cells to a type 2 phenotype with very few Th17 cells compared to 222 
neonates (Fig. 3, K and L). 223 
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CD4+ effector cells have recently been identified in human cord blood (3). We therefore 224 
investigated the relative proportions of CD4+IL-13+ T cells and IL-13+ ILCs in cord blood. 50% 225 
of CD45+cells were CD4+, while only 0.02% were Lin-CD161+ ILCs (Fig. 3M). In keeping 226 
with our observations regarding pulmonary IL-13+ cells in neonatal mice, ILC2s in cord blood 227 
(from healthy term infants) were not the predominant source of IL-13. Instead CD4+ T cells 228 
contributed to the potential pool of neonatal IL-13 (Fig. 3N). Neonatal T cells were positive 229 
for the T-cell receptor and negative for the CD1d dimer expressed on natural killer T cells (Fig. 230 
3O).  231 
 232 
 233 
Allergen exposure in neonatal SCID mice protects from AHR, while Il33-/- mice are unaffected. 234 
To determine the functional significance of the pulmonary IL-13+CD4+ T cells in early life, we 235 
exposed neonatal SCID mice, which lack T, B and NK cells, to HDM for 2 weeks (fig. S3A). 236 
While the WT mice showed the expected increase in AHR (fig. S3B), the neonatal SCID mice 237 
did not exhibit any AHR (fig. S3C). The observed AHR in WT mice correlated with increased 238 
levels of IL-13 and IL-33 which were not apparent in SCID mice (fig. S3, D and E). IL-13 is 239 
known to be critical for the generation of AHR. However, the dependence of AHR on the innate 240 
cytokine IL-33 in neonates has not been investigated. Therefore, we exposed neonatal WT and 241 
Il33-/- mice to HDM from day 3 of life. Neonatal Il33-/-  mice developed equivalent AHR and 242 
an inflammatory response of similar composition and magnitude to WT mice (Fig. 4, A-D). 243 
IL-33 was absent in the Il33-/-  mice as expected but the type 2 cytokines IL-5 and IL-13 were 244 
induced to similar levels in WT and KO mice (Fig. 4, E-G), demonstrating that in neonatal 245 
mice AHR is independent of IL-33 but totally reliant on IL-13. These data underscore the 246 
functional importance of perinatal IL-13+CD4+ T cells in inducing AHR in early life and 247 
suggest pulmonary T cells are a critical source of IL-13 in the immediate postnatal period. 248 
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 249 
Mice lacking IL-13 in CD4+ T cells do not develop AHR in response to allergen. 250 
In order to confirm the importance of T cell derived IL-13 on the generation of allergen 251 
induced AHR we exposed either neonatal WT or Cd4-cre Il-4Il13fl/fl mice to inhaled HDM 252 
or Alternaria. T cells from Cd4-cre Il-4Il13fl/fl mice are unable to generate IL-13 or IL-4 253 
so permit the specifc role of T cell derived IL-4/IL-13 to be investigated. Initial experiments 254 
confirmed the previously observed allergen induced increase in IL-13+CD4+ T cells in WT 255 
mice and established that these cells were absent in the Cd4-cre Il-4Il13fl/fl mice (Fig. 5A). 256 
Confirming our hypothesis, mice lacking these cells did not develop AHR following exposure 257 
to either HDM or Alternaria (Fig. 5, B and C). We next determined the composition of the 258 
pulmonary cellular infiltrate in these mice. The number of eosinophils (Fig. 5, D and E) and 259 
IL-13+ ILC (Fig. 5, F and G) were not significantly different between WT and Cd4-cre Il-260 
4Il13fl/fl mice. Likewise, T cells expressing IL-5 were not affected by the specific loss of IL-261 
13+CD4+ T cells (Fig. 5, H and I). Despite the presence of increased IL-13+ ILC2 with the 262 
capacity to secrete IL-13 (Fig. 5, F and G), there was only a minimal increase in pulmonary 263 
IL-13 levels following HDM or Alternaria exposure (Fig. 5, J and K) in the absence of IL-264 
13+CD4+ T cells. Expression of Muc5ac was increased in neonates exposed to both HDM and 265 
Alternaria (Fig. 5, L and M). In mice lacking IL-13+CD4+ T cells the HDM induced increase 266 
in Muc5ac was ablated (Fig. 5L) indicating that expression is dependent on IL-13 levels. 267 
However, in mice administered Alternaria, allergen induced Muc5ac gene expression was 268 
maintained (Fig. 5M). This suggests IL-13+ ILC2 alone are not sufficient to generate levels of 269 
IL-13 necessary to drive AHR in the absence of IL-13+CD4+ T cells in early life. Thus, mice 270 
lacking IL-13 specifically in CD4+ T cells were completely protected from developing AHR 271 
following exposure to different allergens, underscoring the importance of these cells in the 272 
inception of early life AHR. 273 
13 
 
 274 
Therapeutic manipulation of IL-13+CD4+ T cells protects neonatal mice from developing AHR. 275 
Whilst studies using knockout mice show proof of principle, in order to determine whether it 276 
is possible to translate these findings and therapeutically manipulate neonatal IL-13+CD4+ T 277 
cells which drive allergen induced changes to lung function, we investigated the mechanism of 278 
action of an immunomodulatory agent, the lyophilised bacteria Acinetobacter iwoffii, which is 279 
associated with protection from asthma in children (17) and AHR in adult mouse models (20). 280 
We administered A. iwoffii (a farmyard isolate with strong allergy protective properties) intra-281 
nasally concomitant with HDM to neonatal BALB/c mice from day 3 of life for 3 weeks (Fig. 282 
6A). Neonatal mice that received both the inhaled bacteria and HDM were completely 283 
protected from the development of AHR (Fig. 6B). Moreover, eosinophils were significantly 284 
reduced in the mice that received A. iwoffii (Fig. 6C). Pulmonary IL-33 levels remained 285 
elevated in all mice that received HDM even those that received the bacterial isolate (Fig. 6D), 286 
but in keeping with the AHR results, allergen induced IL-13 levels were almost completely 287 
abrogated in the mice that received A. iwoffii (Fig. 6E). When the lymphoid cellular source of 288 
IL-13 was assessed, numbers of IL-13+ ILCs were increased in the mice that received bacteria 289 
irrespective of allergen exposure (Fig. 6F), but IL-13+CD4+ T cells were significantly reduced 290 
(Fig. 6G). Levels of allergen induced IL-5 were unaffected by the A. iwoffii (Fig. 6H). To 291 
further investigate how the A. iwoffii prevented the recruitment of IL-13+CD4+ T cells we 292 
enumerated pulmonary dendritic cells. In agreement with data in the literature, exposure to 293 
HDM alone resulted in a significant increase in the number of CD11b+ cDCs (Fig. 6I). pDC 294 
and MoDC numbers were also elevated. However, concomitant exposure to A. iwoffii 295 
completely blocked the expansion of CD11b+ cDCs and MoDCs (Fig.6I) correlating with the 296 
reduction in IL-13+CD4+ T cells and improvement in AHR in these mice. These data confirm 297 
the critical role of IL-13 from IL-13+CD4+ T cells for the generation of neonatal AHR and 298 
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show that IL-13+ ILCs cannot compensate for the absence of IL-13 from T cells in inducing 299 
neonatal AHR.  300 
 301 
Discussion 302 
An essential clinical feature of asthma and wheezing in childhood, including infancy and the 303 
pre-school years, is the presence of AHR  (37). In addition, cohort studies have shown the 304 
single most important factor that determines development of asthma in children is AHR in early 305 
life, which may be apparent even before the onset of the manifest symptom of wheezing (38). 306 
In order to identify mechanisms mediating allergen induced disease inception, and targets for 307 
intervention to allow asthma prevention, achieving a reduction in AHR is essential. However, 308 
the underlying molecular mechanisms remained unclear. AHR was the focus of this study in 309 
order to optimally reflect paediatric symptoms. We determined that effector IL-13+ CD4+ cells 310 
are critical for the development of AHR following exposure to either the ILC2 promoting 311 
cytokine rIL-33 or clinically relevant allergens HDM and Alternaria in the first weeks of life. 312 
IL-13+ ILCs were insufficient to compensate for an absence of IL-13+CD4+ T cells in early life, 313 
demonstrated by the lack of AHR in neonatal SCID mice or in mice specifically lacking IL-13 314 
in CD4+ T cells following exposure to inhaled allergen. Mice lacking functional T and B cells 315 
or IL-13+CD4+ T cells did not develop increased levels of IL-13 following allergen exposure 316 
from day 3 of life despite comparable numbers of IL-13+ ILCs. Moreover, administration of 317 
inhaled farm dust bacteria during exposure to HDM to neonatal mice resulted in complete 318 
protection from AHR with a significant reduction in pulmonary IL-13+CD4+ T cells and levels 319 
of IL-13, but sustained elevation of IL-33 and IL-13+ ILCs. Collectively these data show that 320 
in neonatal mice, T cells are an essential early source of IL-13 to drive AHR. Our results 321 
indicate that although ILCs have the potential to generate IL-13 when stimulated with PMA 322 
and ionomycin in vitro, in the absence of IL-13+CD4+ T cells in vivo functional levels of IL-13 323 
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are not generated. Thus, despite the assumption that ILC2s initiate pulmonary allergic immune 324 
responses, this is in fact dependent on age, and in neonatal mice IL-13+CD4+ T cells are critical 325 
for disease inception in early life. This has significant implications for therapies to prevent 326 
wheeze and asthma inception in childhood, since molecular targets that prevent the induction 327 
of type 2 ILCs are unlikely to be effective in preventing early onset disease.  328 
 329 
Key distinctions between adult and neonatal immune responses following HDM exposure were 330 
also shown in a neonatal model that used a single dose of allergen to achieve sensitisation at 331 
day 3, 14 or adult life, followed by allergen challenge a week later (13) . Similarly, previous 332 
neonatal murine studies have shown the importance of the first 2 weeks of life in causing 333 
exaggerated immune responses (39), but did not examine associated AHR or interrogate the 334 
cellular source of the mediators that potentially generate AHR. We used a model of continuous, 335 
low dose allergen exposure, rather than sensitisation followed by allergen challenge several 336 
days later, as this reflects the type of exposure that young children likely experience with 337 
perennial allergens such as HDM and Alternaria. Although ILC2 have been shown to be 338 
important in generating Th2 immunity in experiments with papain or helminths in adult mice  339 
(40, 41) our data indicate that in neonatal mice IL-13+CD4+ T cells drive early life allergen 340 
induced AHR. We cannot rule out the role of T cell derived IL-4 in neonatal allergen-341 
driven responses, and given the potnetial importance of IL-4, future studies are needed 342 
to clarify the relative importance of IL-4 and IL-13 production in this process. In adult 343 
mice, an elegant series of experiments using ILC deficient mice reconstituted with naïve CD4+ 344 
T cells has also shown that activation of primed Th2 cells is independent of ILC2s (42). 345 
However, in contrast to our findings in neonatal mice, the adult Th2 cell activation was 346 
dependent on pulmonary IL-33. Similarly, in response to HDM or papain, adult Th2 cells 347 
secreting IL-13 but not IL-4 have been shown to mediate TCR independent, IL-33 dependent 348 
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innate-like immune responses (43). Thus, interactions between Th2 cells and ILC2 are vital in 349 
developing pathophysiology, but are likely to be contextual depending on environmental or 350 
temporal factors. 351 
 352 
The in utero environment is biased towards Th2 immunity in order to support a successful 353 
pregnancy. CD4+ effector cells with a memory phenotype have previously been identified in 354 
human cord blood (26) and we have also shown the presence of IL-13+ CD4+ cells, but very 355 
few IL-13+ILCs in cord blood from healthy newborns. A specific subpopulation of IL-4+CD4+ 356 
T cells that are present in cord blood from naïve human neonates, but are lost during ageing, 357 
has also been described (44). This distinct subpopulation of IL4+CD4+ cells was only found in 358 
neonates, but not in adults, and supports the hypothesis of an endogenously poised type 2 359 
cytokine profile of T cells in neonates and a link between cytokine production and 360 
developmental stage (44). Using neonatal BALB/c mice we have shown that CD4+ T cells make 361 
a vital contribution to the pool of IL-13 in the lung which drives AHR. Caution should therefore 362 
be exercised when interpreting data from C57BL/6 mice where allergen appears to induce 363 
ILC2s as the major source of IL-13 secreting cells in an IL-33 dependent manner (13). An 364 
important factor that determined our use of BALB/c mice is the direct reflection of the disease 365 
phenotype of our patients with severe wheezing and asthma, incorporating a marked airway 366 
eosinophilia, AHR and remodelling (45, 46), in this strain and protocol of allergen exposure. 367 
Previous murine studies, also in BALB/c mice, have shown that polyclonal stimulation of lung 368 
T cells results in a bias towards IL-4 and IL-5, and increased ratio of GATA3+ T cells compared 369 
to T-bet+ T cells (47). Interestingly, this would appear to be an intrinsic feature of neonatal T 370 
cells since BCG primed lung dendritic cells from either neonates or adults prime adult naïve T 371 
cells towards Th1 whereas a Th2 cytokine response is observed from naïve neonatal T cells. 372 
Cord blood cells, which are reflective of fetal blood, showed a substantial IL-13 response to 373 
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allergen stimulation in vitro, and the newborns had a Th2 cytokine bias that was restricted to 374 
IL-13 (28). Although these results were in peripheral blood rather than the lung, they do 375 
indicate that early life is indeed associated with a skewed IL-13 response. We now show that 376 
T cell derived IL-13 is critical for the inception of allergen induced lung function changes.  377 
 378 
Our data highlight the critical role of T cell derived IL-13 in the neonatal period. Neonatal mice 379 
have a population of IL-13+CD4+ T cells which have the capacity to rapidly promote AHR 380 
when exposed to allergen. Modulating the allergen induced increase in dendritic cells in the 381 
lung, and consequently the IL-13+CD4+ T cells, via a farm dust bacterial isolate specifically 382 
abrogates AHR, even while IL-33 and IL-13+ ILCs are maintained. The concept of the neonatal 383 
‘window of opportunity’ is gathering momentum with regard to the mucosal microbiota  (39)  384 
and we now know that life-long immune homeostasis and susceptibility to immune mediated 385 
diseases (asthma, allergies, bronchiectasis) can be shaped during the postnatal period (22, 48, 386 
49). The specialized neonatal adaptive immune response after birth also has a predisposition to 387 
higher expression of GATA-3+, type 2 cytokine producing pulmonary T cells (47) as a result 388 
of both normal development and in response to environmental exposures. In the current study 389 
we have shown that interventional approaches to prevent AHR and asthma in early life need to 390 
focus on reducing IL-13+CD4+ T cells, rather than IL-13+ ILCs, highlighting the need for age-391 
specific therapeutic approaches in infants and young children compared to adults. 392 
 393 
 394 
 395 
 396 
 397 
 398 
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 399 
Materials and Methods 400 
Study Design 401 
This study aimed to determine the immune mechanisms that drive the inception of airway 402 
hyperresponsiveness in neonatal mice. 403 
Research samples.  404 
Immune cells were collected from the lung tissue of adult and neonatal mice at the times 405 
indicated depending on the experimental setup. Cord blood was collected at delivery of full 406 
term pregnancies. 407 
 408 
Experimental design.  409 
Randomization  410 
In all experiments, mice from the control and experimental groups came from the same cohorts, 411 
were reared under the same environmental conditions, and were age-matched. Adult female 412 
mice were randomly placed in either the control group or the experimental group. Neonatal 413 
mice were of either sex and litters were randomly assigned to control or experimental groups. 414 
 415 
Sample size.  416 
The number of mice analyzed for each different experimental approach is indicated on each 417 
figure. All experiments were repeated at least once with similar sample sizes and a minimum 418 
number of 4 mice per group. 419 
 420 
Animals and reagents 421 
Female BALB/c wild-type and Beige SCID mice were initially obtained from Charles River 422 
(Saffron Walden, UK) and maintained by in-house breeding. Cd4-cre Il-4Il13fl/fl mice(50) on 423 
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a BALB/c background were a kind gift from David Voehringer. Il33-/- mice were a kind gift 424 
from MedImmune Inc. Each mother with its litter was housed separately. Mice were 425 
maintained in specific pathogen–free conditions and given food and water ad libitum. In 426 
individual experiments all mice were matched exactly for age and background strain. All 427 
procedures were conducted in accordance with the Animals (Scientific procedures) Act 1986. 428 
Recombinant mouse IL-33 (50μg/kg) for intra-nasal administration was purchased from R&D 429 
Systems (UK).  430 
 431 
Allergen challenge 432 
In experiments to assess the effect of allergen challenge on allergic airways disease 3 day old 433 
neonatal mice and adults (6-8 weeks) received intra-nasal administration of either HDM or 434 
Alternaria alternata (Greer, Lenior, NC, USA). From birth to 2 weeks of age mice were 435 
administered 20μg house dust mite (HDM) extract, 5μg Alternaria or 10μl phosphate buffered 436 
saline (PBS), three times a week. Adult mice received 25μg HDM or 10μg Alternaria. All 437 
outputs were assessed at 24 hours after allergen challenge  (51).  438 
 439 
Bacteria and allergen co-exposure 440 
BALB/c mice were exposed to intermittent intra-nasal Acinetobacter iwoffii F78 (A. iwoffii 441 
F78) (1.3x108cfu first 2 weeks, then 2x108cfu  (52) (a kind gift from Johann Bauer) or PBS 442 
followed by HDM (10μg first 2 weeks, then 15μg) or PBS for 3 weeks starting on day 3 of life 443 
for 3 weeks. All outputs were assessed 24 hours post final challenge as described below. 444 
 445 
Measurement of airway hyperresponsiveness 446 
Airways resistance was calculated using the flexivent small animal ventilator (Scireq) using 447 
our established protocols (29).  448 
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Mice were anesthetized with pentobarbital sodium (50mg/kg intra-peritoneal) and ketamine 449 
(100mg/kg intra-muscular), tracheostomised and connected to the flexivent ventilator via a 450 
blunt-ended 21-gauge needle (neonate) or 19-gauge needle (adult). The mice were ventilated 451 
with an average breathing frequency of 150 breaths/minute; tidal volume of 10ml/kg body 452 
weight; positive end-expiratory pressure approximately 2cm H2O. Changes in resistance to 453 
increasing to increasing concentrations of nebulized methacholine (3 -3 100mg/ml were 454 
calculated from the snapshot perturbation measurements.Resultant data was fitted using 455 
multiple linear regression to the single compartment model in the form: pressure = resistance x 456 
flow + elastance x volume + fitting constant.  457 
 458 
Inflammation and cell recovery 459 
Bronchoalveolar lavage (BAL) was performed with PBS via a tracheal cannula. The volume of 460 
BAL fluid instilled was 3 x 200µl aliquots for neonatal mice, 3 x 300 µl for 3 week old mice  461 
and 3 x 400µl in adults (29). After lavage, the large left lobe of the lung was mechanically 462 
chopped and incubated at 37°C for 1 hour in complete media (RPMI + 10% fetal calf serum, 463 
2mM L-glutamine, 100U/ml penicillin/streptomycin) containing 0.15mg/mL collagenase 464 
(Type D, Roche Diagnostics) and 25mg/mL DNAse (Type 1, Roche Diagnostics). Cells were 465 
recovered by filtration through a 70-µm nylon sieve (Falcon, BD Biosciences, MA), washed 466 
twice, resuspended in 1ml complete media, and counted in a haemocytometer (Immune 467 
Systems). The total cell yield was quantified by haemocytometer. All cell counts were 468 
performed blind by the same observer. 469 
 470 
Flow cytometry 471 
To reduce non-specific binding, cells were incubated with rabbit serum (Sigma) for 15 minutes 472 
before staining. Where staining for intracellular cytokines, single cell suspensions were 473 
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incubated at 37 oC in complete RPMI for 4 hours, in the presence of 20 ng/ml phorbol 12-474 
myristate 13-acetate (PMA, Sigma-Aldrich), 1.5μg/ml ionomycin free acid from Streptomyces 475 
conglobatus (Merck) and 5μg/ml Brefeldin A (Sigma-Aldrich). Cells were subsequently 476 
washed in PBS and stained with LIVE/DEAD™ Fixable Blue Dead Cell Stain (Thermo 477 
Fisher/Life Technologies), as per manufacturer’s directions, before washing twice in PBS.  Cell 478 
suspensions were then stained with fluorochrome-conjugated monoclonal antibodies to surface 479 
markers (see table/supplementary methods) in staining buffer (PBS containing 1% BSA and 480 
0.01% sodium azide) for 20 minutes at 4 oC. Cells were then washed twice in staining buffer 481 
and fixed in IC Fixation Buffer (Thermo Fisher/eBioscience) for 15 minutes at room 482 
temperature. Where necessary, fixed cells were permeabilized using Permeabilization Buffer 483 
(Thermo Fisher/eBioscience) and stained with fluorochome-conjugated antibodies to 484 
intracellular cytokines (see table/supplementary methods) in Permeablization buffer for 20 485 
minutes at 4 oC. ‘Fluorescence minus one’ (FMO) controls for extracellular and intracellular 486 
antigens were used on matched tissue samples for quality control purposes and to assist with 487 
gating. Data were acquired on an LSR Fortessa using FACSDIVA™ software (both BD) and 488 
analysed using FlowJo software (v10, Tree Star). For ILC identification in mouse samples, 489 
lineage exclusion gates consisting of the surface markers TCRβ, TCRγδ, CD3e, CD5, CD19, 490 
CD11b, CD11c, FCεR1, GR-1, F4/80, NKp46 and TER-119 were used (Supplementary table 491 
1). For ILC identification in human samples, a lineage exclusion gate consisting of CD14, 492 
CD16, CD19, CD20, CD3 and CD56 was employed. 493 
 494 
Quantification of cytokines 495 
Lung tissue was homogenized at 50mg/ml in HBSS (Gibco) containing protease inhibitor 496 
tablets (Roche Diagnostics), centrifuged at 800 x g for 20minutes and the supernatant was 497 
collected. Cytokines were analyzed in lung homogenate supernatants. Paired antibodies for 498 
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mouse interleukin IL-33 (R&D Systems) and IL-5 (BD Bioseciences) were used in 499 
standardized sandwich ELISA’s according to the manufacturer's protocols.  IL-13 was 500 
measured using a Quantikine kit (R&D Systems) as per the manufacturer’s protocol. 501 
 502 
qPCR 503 
RNA was extracted from the lung using the Qiagen miRNeasy Plus Mini Kit, following the 504 
manufacturer’s instructions. Reverse transcription was performed with 1-2 µg RNA using the 505 
High Capacity cDNA Reverse Transcription Kit (Applied Biosystems), following the 506 
manufacturer’s instructions. Generated cDNA was used for quantitative real-time PCR analysis 507 
using TaqMan® Fast Advanced Master Mix (Applied Biosystems) and quantified on the ViiA 508 
7 (Applied Biosystems). Relative gene expression was determined via normalisation to the 509 
housekeeping gene Gapdh. All TaqMan® primers were purchased from ThermoFisher 510 
Scientific. Primers: Gapdh (Mm99999915_g1), Dye: FAM-MGB. Il5 (Mm00439646_m1), 511 
Dye: FAM-MGB. Il13 (Mm00434204_m1), Dye: FAM-MGB. Muc5ac (Mm01276726_g1), 512 
Dye: FAM-MGB. Muc5b (Mm00466391_m1), Dye: FAM-MGB. 513 
 514 
Statistical analysis 515 
All results were expressed as median and interquartile range and data were analyzed using 516 
GraphPad Prism 7 software (GraphPad Software). Non-parametric tests (Mann Whitney U) 517 
were used to detect differences between groups and statistical significance accepted when p < 518 
0.05. *p <0.05, **p < 0.01, and ***p < 0.001  519 
 520 
Supplementary Materials 521 
Fig. S1. Defining IL-13+ CD4+ T cells and ILCs in neonatal mice. 522 
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Fig. S2. Alternaria induces AHR in neonatal mice. 523 
Fig. S3. Allergen exposure in neonatal SCID mice does not result in AHR. 524 
Table S1. Antibodies used for flow cytometry. 525 
 526 
 527 
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Figures captions: 731 
Fig. 1. T cells and ILCs are equally important sources of IL-13 in neonatal mice exposed 732 
to rIL-33. 733 
(A) BALB/c mice ages 3 days and 6-8 weeks were exposed to intermittent intra-nasal 734 
recombinant IL-33 (rIL-33) (50μg/kg) or PBS for 2 weeks (). Harvest was carried out 24 735 
hours post final dose. Numbers of CD3+CD4+IL-13+ T cells compared to innate lymphoid cells 736 
(LinnegCD45+CD90+IL-13+) in lungs of (B) adult and (C) neonatal BALB/c mice. (D) 737 
Pulmonary eosinophils (SiglecF+CD11clow/neg) enumerated by flow cytometry. Airway 738 
resistance to methacholine (Mch) in (E) neonatal and (F) adult mice exposed to intra-nasal rIL-739 
33. (G) IL-13 gene expression in the lung. (H) Levels of IL-13 in the lungs. (I) IL-5 gene 740 
expression in the lung. Expression of (J) Muc5ac and (K) Muc5b. N=6-8 rIL-33, N=4-5 PBS.  741 
Data representative of at least 2 experiments.  *p<0.05, *p<0.01, ***p<0.001. 742 
 743 
Fig. 2. In response to allergen T cells and ILCs are equally important sources of IL-13. 744 
Airway responsiveness to methacholine (Mch) in (A) neonatal and (B) adult mice. (C) 745 
Pulmonary eosinophils (SiglecF+CD11clow/neg). Numbers of LinnegCD45+CD90+IL-13+ILCs 746 
and CD3+CD4+IL-13+ T cells in lungs of (D) adult and (E) neonatal mice. (F) Levels of IL-13 747 
in the lung of mice exposed to HDM. . IL-13+ILCs and T cells in lungs of (G) adult and (H) 748 
neonatal mice exposed to ALT. (I) Levels of IL-13 in the lung of mice exposed to ALT. N=6-749 
8 allergen exposed, N=4-6 PBS. Data representative of 2 experiments. *p<0.05, **<0.01, 750 
***p<0.001. 751 
 752 
Fig. 3. IL-13 is a feature of allergen activated neonatal T cells. 753 
CD4+ T cells from house dust mite HDM and Alternaria alternata (ALT) treated neonatal and 754 
adult mice were classified as either IL-13+ or IL-13neg and analysed for surface markers. Cells 755 
30 
 
were defined as either (A & B) memory-like (CD44+CD62Llow), (C & D) epithelial associated 756 
(CD103+) or (E & F) activated (CD69+/ICOS+). The proportion of neonatal and adult CD4+ T 757 
cells from (G & H) PBS control, (I & J) HDM treated or (K & L) ALT exposed mice 758 
expressing cytokine were also enumerated. N=7-9 allergen exposed, N=5 PBS. Data 759 
representative of 2 experiments. Human cord blood was analysed for (M) total CD4+ T cells 760 
and total ILC2 (Lin-CD161+CD127+CRTH2+CD56-) and (N) IL-13+ CD4+ T cells and IL-13+ 761 
ILC2. (O) Neonatal T cells expressed TCR- but lacked expression of CD1d dimer. Values are 762 
expressed as a percentage of live CD45+ lymphoid cells. N=20. *p<0.05, **<0.01, ***p<0.001. 763 
 764 
Fig. 4. IL-33 is not critical for initiation of allergic airways disease phenotype. 765 
3 day old wild type BALB/c (WT) and Il33-/-mice were exposed to intermittent doses of house 766 
dust mite (HDM) or PBS. (A) Airway responsiveness to methacholine (Mch) in neonatal WT 767 
and Il33-/- mice. (B) Pulmonary eosinophils (SiglecF+CD11clow/neg). Numbers of pulmonary 768 
(C) LinnegCD45+ IL-13+ILCs and (D) CD3+CD4+IL-13+ T cells. Levels of (E) IL-33, (F) IL-5 769 
and (G) IL-13 in the lung. N=7-12 HDM, N=6-8 PBS. Data representative of 2 experiments. 770 
*p<0.05, **p<0.01, ***p<0.001. 771 
 772 
Fig. 5. T cell derived IL-13 is essential for the inception of AHR.  773 
3 day old wild type BALB/c (WT) and Cd4-cre Il-4Il13fl/fl (CD4Cre) mice were exposed to 774 
intermittent doses of house dust mite (HDM), Alternaria alternata (ALT) or PBS for 2 weeks. 775 
(A) Representative flow cytometry plots of cytokine expressing (IL-5 and/or IL-13) CD3+CD4+ 776 
T cells. Airway responsiveness to methacholine (Mch) in neonatal mice exposed to (B) HDM 777 
or (C) ALT. Lung eosinophils enumerated by flow cytometry in mice exposed to (D) HDM or 778 
(E) ALT. LinnegCD45+CD90+IL-13+ILCs in mice exposed to (F) HDM or (G) ALT. IL-5+T 779 
cells to in mice exposed to  (H) HDM or (I) ALT. IL-13 levels in mice exposed (J) HDM or 780 
31 
 
(K) ALT. Muc5ac gene expression in mice exposed to (L) HDM  or (M) ALT. N=6-8 allergen 781 
exposed, N=4-6 PBS. Data representative of at least 2 experiments. *p<0.05, **<0.01, 782 
***p<0.001. 783 
 784 
Fig. 6. Protection from AHR in neonatal mice can be achieved by reduction of IL-13+ T 785 
cells. 786 
(A) BALB/c mice aged 3 days were exposed to intermittent intra-nasal Acinetobacter iwoffii 787 
F78 (A. iwoffii F78) (1.3x108cfu first 2 weeks, then 2x108cfu) or PBS () followed by house 788 
dust mite (HDM) (10μg first 2 weeks, then 15μg) or PBS for 3 weeks (). Analysis was carried 789 
out 24 hours post final dose. (B) Airway hyperresponsivness (AHR) to methacholine (Mch) 790 
after 3 weeks of A. iwoffii F78 and HDM co-exposure. (C) Numbers of eosinophils 791 
(SiglecF+CD11clow/neg) in lung. (D) IL-33 and (E) IL-13 levels from lung homogenate. (F) 792 
Numbers of innate lymphoid cells (Lin-CD45+IL-13+) and (G) CD3+CD4+IL-13+ T cells.  (H)  793 
IL-5 levels in the lung tissue. (I) Dendritic cell (DC) populations in the lung enumerated by 794 
flow cytometry. cDC (CD11b+CD11chigh), pDC (CD11cintLy6c+CD64-), MoDC 795 
(CD11c+Ly6c+CD64+). N=8 for HDM and bacteria exposed groups, N=5 for PBS. *p<0.05, 796 
**p<0.01, ***p<0.001. Data representative of 3 experiments. 797 
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 824 
Supplementary Fig. 1. Defining IL-13+ CD4+ T cells and ILCs in neonatal mice 825 
(A) Hierarchical (left to right) gating strategy for IL-13+ CD4+ T cells, defined as live, singlet, 826 
CD45+, FSC/SSC low (lymphoid), CD4+, CD3+, CD8- cells with positive intracellular IL-13 827 
staining were then selected. (B) Hierarchical (left to right) gating strategy for IL-13+ ILCs, 828 
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defined as live, singlet, CD45+ lymphoid, lineage- (TCRβ, TCRγδ, CD3e, CD5, CD19, CD11b, 829 
CD11c, FCεR1, GR-1, F4/80, NKp46 and TER-119) –negative, CD90.2+ cells with positive 830 
intracellular IL-13 staining. Plots in (A) and (B) are from representative lung samples from IL-831 
33-treated neonatal mice. (C) Percentages of IL-13+ Lineage- CD45+ lymphoid cells in lung 832 
tissue expressing typical ILC surface markers. (D) Representative histograms showing surface 833 
expression of ST2, ICOS and CD25 on pulmonary IL-13+ CD90.2+ CD45+ Lineage- ILCs, 834 
relative to FMO controls. (E) Representative histograms showing CD127 surface staining on 835 
IL-13+ CD90.2+ Lineage- ILC2 from lungs of neonatal BALB/c (left) and C57BL/6 mice 836 
treated with HDM or PBS for 2 weeks, relative to FMO controls. Data are representative of 4-837 
8 replicate animals per group. 838 
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Supplementary Fig. 2. Alternaria induces AHR in neonatal mice 843 
(A) Day 3 old and adult BALB/c mice were exposed to intermittent doses of Alternaria 844 
alternata (ALT) or PBS for 2 weeks ().  Analysis was carried out 24 hours post final dose. 845 
Airway resistance to methacholine (Mch) in (B) neonatal and (C) adult mice. (D) Numbers of 846 
eosinophils (SiglecF+CD11clow/neg) in lung enumerated by flow cytometry. N=6-8 ALT, n=4-6 847 
PBS. Data representative of 2 experiments. *p<0.05, **<0.01, ***p<0.001. 848 
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Supplementary Fig. 3. Allergen exposure in neonatal SCID mice does not result in AHR. 852 
(A) Day 3 old WT BALB/c and beige SCID mice were exposed to intermittent doses of house 853 
dust mite (HDM) or PBS for 2 weeks ().  Analysis was carried out 24 hours post final dose. 854 
Airway resistance to methacholine (Mch) in (B) WT mice and (C) SCID mice. Levels of (D) 855 
IL-13 and (E) IL-33 from lung homogenates of WT mice compared to SCID mice. N=7-12 856 
HDM, n=6-8 PBS. Data representative of 2 experiments. *p<0.05, **p<0.01, ***p<0.001. 857 
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Antigen Clone Fluorochrome Target species Manufacturer 
CD103 2E7 FITC 
Mouse 
Thermo Fisher/ 
eBiosciences 
CD11b M1/70 APC Mouse Biolegend 
CD11c N418 APC or APC Cy7 Mouse Biolegend 
CD127 A7R34 BV711 Mouse Biolegend 
CD19 ebio 1D3 APC Mouse Biolegend 
CD25 PC61 BV510 Mouse Biolegend 
CD3e 145-2C11 APC cy7 or PE Cy7 Mouse Biolegend 
CD4 RM4-5 BV421 or APC Cy7 Mouse Biolegend 
CD44 IM7 PERCP Cy5.5 Mouse Biolegend 
CD45 30-F11 
PerCP Cy5.5 or 
BV711 or 
PE/Dazzle™ 594  Mouse 
Biolegend 
CD5 53-7.3 APC Mouse Biolegend 
CD62L MEL-14 BV605 Mouse Biolegend 
CD64 X54-5/7.1 BV421 Mouse Biolegend 
CD8a 53-6.7 BV605 Mouse Biolegend 
CD90.2 53-2.1 BV605 Mouse Biolegend  
F4/80 BM8 APC Mouse Biolegend 
FCεR1 MAR1 APC Mouse Biolegend 
GR-1 RB6-8C5 APC Mouse Biolegend 
IA/IE M5/114.15.2 PECRP cy5.5 Mouse Biolegend 
ICOS 7E.17G9 PE cy7 Mouse Biolegend 
43 
 
IFNγ XMG1.2 FITC Mouse Biolegend 
IL-10 JES5-16E3 APC Mouse Biolegend 
IL-13 ebio 13A PE 
Mouse 
Thermo Fisher/ 
eBiosciences 
IL-17A TC11-18H10 
Alexa Fluor 700 or 
PERCP Cy5.5 Mouse 
Biolegend 
IL-5 TRFK5 BV421 Mouse Biolegend 
Ly6G 1A8 BV510 Mouse Biolegend 
Nkp46 29A1.4 
PE/Dazzle™ 594 or 
BV605 Mouse 
Biolegend 
Siglec F E50-2440 PE Mouse BD 
ST2 DJ8 FITC Mouse MD Biosciences 
TCRβ H57-597 APC Mouse Biolegend 
TCRγδ ebio GL3 APC Mouse Biolegend 
TER-119 TER-119 APC Mouse Biolegend 
CD11c 3.9 FITC Human Biolegend 
CD123 6H6 FITC Human Biolegend 
CD127 A019D5 PERCP Cy5.5 Human Biolegend 
CD14 63D3 FITC Human Biolegend 
CD16 B73.1 FITC Human Biolegend 
CD161 HP-3G10 PE Cy7 Human Biolegend 
CD19 HIB19 FITC Human Biolegend 
CD1a HI149 FITC Human Biolegend 
CD20 2H7 FITC Human Biolegend 
44 
 
CD3 OKT3 BV510 Human Biolegend 
CD34 581 FITC Human Biolegend 
CD4 OKT4 Alexa Fluor 700 Human Biolegend 
CD45 HI30 BV605 Human Biolegend 
CD5 L17F12 FITC Human Biolegend 
CD56 HCD56 PE Texas Red Human Biolegend 
CD8 SK1 FITC Human Biolegend 
CRTH2 BM16 APC Cy7 Human Biolegend 
FCεR1 AER-37 FITC Human Biolegend 
IL-13 JES10-5A2 PE Human Biolegend 
 859 
Table S1. Antibodies used for flow cytometry 860 
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